236 studies on GIP-R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
The development of highly effective weight loss medications is crucial for addressing the global obesity epidemic, which contributes to numerous health complications. While individual GIP RAs and amylin agonists show …
This study highlights Kisspeptin-10 as a promising novel therapeutic candidate for the management of obesity and type 2 diabetes. Its multifaceted action, involving both the enhancement of beneficial gut hormones and …
Tirzepatide has already demonstrated significant efficacy, and exploring higher or alternative dosing strategies could further optimize patient outcomes by potentially enhancing glycemic control and weight loss. This …
The successful completion of this Phase 3 trial is a significant milestone, as Tirzepatide (a dual GIP and GLP-1 receptor agonist) has already demonstrated robust efficacy in adults with Type 2 Diabetes and obesity. I…
This real-world study provides compelling evidence that treatment persistence is a critical determinant for maximizing the comprehensive benefits of Tirzepatide across the spectrum of Cardio-Metabolic-Kidney Syndrome.…
The substantial and clinically meaningful weight loss achieved with once-weekly Mazdutide positions it as a highly promising therapeutic agent for obesity and overweight. The dual agonism of GLP-1 and GIP receptors ap…
This study highlights the potential of Mazdutide as a highly effective treatment option for type 2 diabetes, particularly in the Chinese adult population, addressing both glycemic control and significant weight manage…
This comprehensive network meta-analysis provides compelling evidence that anti-diabetic agents are not only effective in managing diabetes but also hold significant promise for treating MASH, a condition with limited…
The successful completion of this Phase 1/2 trial for IBI362 could significantly impact the landscape of obesity treatment, particularly for the Chinese patient population. If IBI362 demonstrates a favorable safety pr…
If successful, this study could establish Mazdutide as a promising new therapeutic option for Alcohol Use Disorder (AUD), potentially offering a novel mechanism of action (via GLP-1/GIP agonism affecting reward pathwa…
The development of multi-agonist incretin therapies and novel non-incretin pathways represents a critical advancement, offering more potent and comprehensive treatment options for obesity and Type 2 Diabetes than ever…
The successful outcome of this trial could represent a paradigm shift in managing the complex interplay of Type 1 Diabetes and obesity. If Tirzepatide proves safe and effective, it could offer a novel therapeutic opti…
This study provides crucial economic evidence for healthcare payers and policymakers in the US, suggesting that the superior efficacy of tirzepatide translates into significant long-term health benefits and a favorabl…
This study provides crucial initial evidence that KN069's novel dual mechanism—acting as a GLP-1R (glucagon-like peptide-1 receptor) agonist (mimicking a hormone that promotes insulin release and reduces appetite) and…
The widespread presence of unidentified impurities in commonly used compounded medications poses a significant patient safety risk, potentially altering the drug's efficacy, stability, or causing unforeseen adverse ef…
If the EXER-MED trial demonstrates that combining exercise with tirzepatide leads to significantly better outcomes than medication alone, it could redefine the standard of care for obesity management. This research ha…
The successful completion of this Phase 1 study is a significant step forward in addressing pediatric obesity, a condition with limited pharmacological interventions. Tirzepatide, a dual GLP-1 and GIP receptor agonist…
This case highlights a potential adverse dermatological reaction to tirzepatide, suggesting that GLP-1/GIP receptor agonists might, in rare instances, trigger or exacerbate autoimmune conditions like psoriasis. This o…
These findings provide compelling evidence that tirzepatide can fundamentally alter the disease classification for a significant number of individuals with obesity and overweight, moving them into lower-risk BMI categ…
Tirzepatide not only facilitates significant weight loss but also enables a substantial proportion of individuals with obesity to achieve healthier BMI categories, which is directly associated with profound improvemen…
This study provides compelling evidence that tirzepatide, a dual GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, is significantly more effective than semaglutid…
This research provides compelling evidence that Tirzepatide, a dual GIP/GLP-1 receptor agonist, may offer a novel therapeutic approach to improve outcomes for obese patients after TAVR. By significantly reducing subcl…
The investigation of eloralintide, particularly in combination with tirzepatide, represents a significant step in developing next-generation treatments for obesity. If eloralintide demonstrates a favorable safety and …
This study is significant because it explores a novel therapeutic approach for two intertwined and devastating conditions: Alcohol Use Disorder and Metabolic Alcohol-associated Liver Disease. If successful, tirzepatid…
This feasibility study could provide crucial preliminary evidence for a novel and highly effective treatment strategy for obesity-related hypertension in a vulnerable young adult population. If successful, it could es…
This research highlights that tirzepatide offers substantial cardiovascular benefits, specifically in reducing blood pressure and improving heart function, independent of its known metabolic effects. The observed modu…
This research is highly significant as it targets a critical unmet need in Type 2 Diabetes management: patients who do not achieve adequate glycemic control even with potent GLP-1 or GLP-1/GIP receptor agonists. LY345…
This study provides compelling evidence that Tirzepatide offers substantial cardiovascular protection beyond its established glucose-lowering and weight-loss benefits, positioning it as a critical therapy for patients…
This study provides compelling evidence that tirzepatide, a dual GLP-1 and GIP receptor agonist, offers substantial cardiovascular protection beyond its established glycemic control and weight loss benefits in patient…
This study provides compelling evidence that Tirzepatide, a dual GIP and GLP-1 receptor agonist, significantly improves cardiovascular outcomes in patients with Type 2 Diabetes and high cardiovascular risk. This posit…
This landmark study provides compelling evidence that Tirzepatide, a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, offers substantial cardiovascular prot…
These findings are profoundly significant, as they establish Tirzepatide as a potent agent for cardiovascular risk reduction in patients with Type 2 Diabetes and existing cardiovascular disease, moving beyond its know…
The findings from SURPASS-CVOT establish tirzepatide as a potent therapeutic agent for reducing cardiovascular risk in patients with type 2 diabetes, offering benefits beyond its metabolic effects. This is particularl…
Understanding tirzepatide's effects on skeletal muscle is critically important, as preserving muscle mass during weight loss is a key challenge, especially in obesity. If tirzepatide can mitigate muscle loss or even i…
This study is crucial for understanding Tirzepatide's long-term efficacy and safety outside of highly controlled clinical trial environments. If successful, the findings could significantly inform clinical guidelines …
This novel evidence strongly suggests that tirzepatide could represent a groundbreaking therapeutic strategy for cocaine use disorder (CUD). Its dual action on GLP-1 and GIP receptors appears to modulate reward pathwa…
This first-of-its-kind case report strongly suggests that Tirzepatide, a dual GLP-1/GIP receptor agonist, may offer a novel and highly effective therapeutic avenue for Lichen Planus. The observed complete remission an…
Understanding GIP's long-term effects on bone is critically important given the widespread use of GIP receptor (GIPR) agonists like tirzepatide for obesity and type 2 diabetes, conditions often associated with comprom…
This study provides valuable real-world insights into the comparative safety profiles of tirzepatide, semaglutide, and liraglutide, which can complement findings from controlled clinical trials. The observed differenc…
This study highlights a crucial aspect of Tirzepatide's efficacy: its ability to preserve fat-free mass during weight loss is strongly linked to enhanced glycaemic control. This finding suggests that Tirzepatide offer…
This study is crucial because it provides real-world evidence supporting Tirzepatide as a highly effective treatment intensification strategy for Type 2 Diabetes patients who are not adequately controlled on GLP-1 RAs…
The study, currently underway, aims to demonstrate the significant efficacy of Tirzepatide in reducing liver fat deposition in patients with Type 2 Diabetes and NAFLD with advanced fibrosis. Based on Tirzepatide's wel…
This case report highlights a rare but serious adverse event associated with tirzepatide use, particularly in individuals without pre-existing diabetes or obesity. Clinicians must be vigilant for symptoms of ketoacido…
This commentary underscores the critical importance of addressing metabolic comorbidities in inflammatory diseases like psoriatic arthritis. The hypothetical findings suggest that combining an IL-17A inhibitor with a …